Bruker Corp Stock Price, News & Analysis

Bruker (Nasdaq: BRKR) has launched the X4 POSEIDON™, a high-performance benchtop 3D X-ray microscope (XRM) utilizing micro-Computed Tomography technology. The system features a high-end X-ray source that delivers over 10x improvement in 3D resolution compared to similar instruments.

Key features include:

• Large field-of-view high-efficiency detector with optional high-resolution scientific CMOS detector
• 3DxSUITE software with automated protocols and multi-language support
• Low maintenance design for enhanced uptime and reduced ownership costs
• Field-upgradable options for future expansion

The X4 POSEIDON targets applications in geosciences, pharmaceutical R&D, QA/QC, composite materials, batteries, renewable energy, microelectronics, and life sciences including bone, dental, soft tissue, and biological research.

Bruker (Nasdaq: BRKR) announced major advancements in proteomics technology and software at the 21st Annual US HUPO Conference. The company previewed the timsTOF Ultra 2 system with new Athena Ion Processor (AIP), showing 15-20% improvement in protein identification and 20-25% increase in peptide identifications for single-cell proteomics.

Key announcements include:

• Launch of DeutEx™ software for hydrogen-deuterium exchange analysis
• OmniScape™ 2025b with 10x increase in de novo sequencing performance
• Enhanced ProteoScape™ V.2025c with improved Spectronaut® and GlycoScape™ capabilities
• TwinScape™ cloud-based AI monitoring solution for proteomics quality control

The new AIP technology, expected to launch at ASMS 2025, enables better ion transfer and shows similar improvements in immunopeptidomics. GlycoScape v.2025c increases glycopeptide identification by 6x-10x, enabling comprehensive glycoform profiling.

Bruker (BRKR) announced major advancements in spatial biology to be unveiled at AGBT 2025, including four key innovations: CosMx Whole Transcriptome Panel (WTX), capable of detecting over 18,000 RNA transcripts at single-cell resolution; expansion of GeoMx protein panel to 1,000-plex capability; launch of PaintScape, a platform for 3D genome visualization; and enhanced CellScape PowerOMX software engine for spatial proteomics.

The WTX assay will begin taking orders in April with summer shipments, while a Mouse version is expected later in 2025. The expanded GeoMx 1K Panel is scheduled for summer release. The company also announced the Sapphire Spatial Program, offering premium services for CosMx SMI users, and extended collaboration with Weill Cornell Medicine on the Spatial Atlas of Human Anatomy (SAHA) initiative to map 30 non-diseased organs.

Bruker (BRKR) has announced that its Board of Directors has approved a quarterly cash dividend of $0.05 per share on the Company's common stock. The dividend will be paid on March 28, 2025 to stockholders of record as of March 17, 2025.

Bruker (BRKR) has announced its senior leadership's participation in four major investor conferences in early 2025. The schedule includes:

• Citi 2025 Unplugged Medtech and Life Sciences Access Day in New York City (February 27, 2:30 PM ET)
• TD Cowen 45th Annual Health Care Conference in Boston (March 5, 11:10 AM ET)
• Barclays 27th Annual Global Healthcare Conference in Miami (March 11, 2:30 PM ET)
• Leerink 2025 Global Healthcare Conference in Miami (March 12, 11:20 AM ET)

All presentations will be accessible via live audio webcasts on Bruker's Investor Relations website. Replay recordings will remain available for at least 30 days after each event in the 'Events & Presentations' section.

Bruker (BRKR) reported Q4 2024 revenues of $979.6 million, up 14.6% year-over-year, with organic revenue growth of 3.9%. The company's Q4 non-GAAP operating margin maintained at 18.1%, with Q4 non-GAAP diluted EPS reaching $0.76, up 8.6% year-over-year.

For full-year 2024, revenues reached $3.37 billion, showing 13.6% growth, with organic revenue up 4.0%. The company's FY 2024 non-GAAP diluted EPS was $2.41, down 6.6% due to strategic acquisitions impact in H1-24.

Looking ahead, Bruker initiated FY 2025 guidance with expected revenue between $3.47-3.54 billion (3-5% growth) and non-GAAP EPS of $2.67-2.72 (11-13% growth). The company completed several strategic acquisitions in 2024, expanding into spatial biology, molecular diagnostics, and lab automation markets.

Bruker (BRKR) has announced its upcoming fourth quarter and fiscal year 2024 financial results release, scheduled for Thursday, February 13, 2025, before market opening. The company will host a conference call and webcast at 8:30 a.m. Eastern Standard Time to discuss results and current business trends.

Investors can access the webcast through Bruker's investor relations website and view an accompanying slide presentation. For telephone access, participants can dial 1-888-437-2685 (U.S. toll-free) or +1-412-317-6702 (international). Pre-registration is available to expedite call entry. A replay will be accessible until March 13, 2025, via 1-877-344-7529 (U.S. toll-free) or +1-412-317-0088 (international) using code 5344184.

Bruker (Nasdaq: BRKR) has launched the LUMOS™ II ILIM, a quantum cascade laser (QCL) based infrared imaging microscope designed for pharmaceutical and life science research. The device features a patented coherence reduction method for artifact-free infrared laser imaging in both transmission and reflection modes.

The microscope offers ultrafast IR imaging capabilities over large areas with enhanced spatial resolution. Key features include a large field of view, complete automation, and the ability to rapidly determine chemical complexity in biological tissues. The system integrates with Bruker's MALDI Imaging methods for multimodal tissue characterization and includes AI-powered data evaluation.

According to Dr. Guillaume Mabilleau from Centre Hospitalier Universitaire Angers, the microscope's speed and QCL technology represent a significant advancement for clinical research, particularly in bone disease diagnosis and treatment. The system also supports pharmaceutical tablet inspection and particle identification with automated sampling, and includes a Python interface for customization.

Bruker (BRKR) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company will be represented by Frank Laukien (Chairman, President & CEO), Mark Munch (Executive Vice President & President of Bruker Nano Group), and Gerald Herman (Executive Vice President & CFO).

The presentation is scheduled for Monday, January 13th, 2025, at 3:45 PM Pacific Standard Time. Investors can access a live audio webcast through the company's investor relations website at ir.bruker.com. A replay will be available in the 'Events & Presentations' section for 30 days following the event.